Benzinga | Jul 30, 2020 07:46AM EDT

Blueprint Medicines Q2 EPS $(2.28) Misses $(2.14) Estimate, Sales $8.34M Beat $6.60M Estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(2.14) by 6.54 percent. This is a 11.76 percent decrease over losses of $(2.04) per share from the same period last year. The company reported quarterly sales of $8.34 million which beat the analyst consensus estimate of $6.60 million by 26.41 percent. This is a 63.27 percent increase over sales of $5.11 million the same period last year.